Potential impacts of prolonged absence of influenza virus circulation on subsequent epidemics

Simon P. J. de Jong[1]*, Zandra C. Felix Garza[1]*, Joseph C. Gibson[1]*, Alvin X. Han[1], Sarah van Leeuwen[1], Robert P. de Vries[2], Geert-Jan Boons[2,3,4,5], Marliek van Hoesel[1], Karen de Haan[1], Laura E. van Groeningen[1], Katina D. Hulme[1], Hugo D. G. van Willigen[1], Elke Wynberg[1,6], Godelieve J. de Bree[7], Amy Matser[6], Margreet Bakker[1], Lia van der Hoek[1], Maria Prins[6,7], Neeltje A. Kootstra[8], Dirk Eggink[1,9], Brooke E. Nichols[1,10], Menno D. de Jong[1]† & Colin A. Russell[1,10]†

* Contributed equally, † Contributed equally

[1] Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

[2] Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

[3] Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA

[4] Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands

[5] Department of Chemistry, University of Georgia, Athens, GA, USA

[6] Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands

[7] Department of Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

[8] Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

[9] Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

[10] Department of Global Health, School of Public Health, Boston University, Boston, MA, USA

Correspondence to Colin A. Russell, Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands, c.a.russell@amsterdamumc.nl.

Summary

Background

During the first two years of the COVID-19 pandemic, the circulation of seasonal influenza
viruses was unprecedentedly low. This led to concerns that the lack of immune stimulation to
influenza viruses combined with waning antibody titres could lead to increased susceptibility
to influenza in subsequent seasons, resulting in larger and more severe epidemics.

Methods

We analyzed historical influenza virus epidemiological data from 2003-2019 to assess the
historical frequency of near-absence of seasonal influenza virus circulation and its impact on
the size and severity of subsequent epidemics. Additionally, we measured haemagglutination
inhibition-based antibody titres against seasonal influenza viruses using longitudinal serum
samples from 165 healthy adults, collected before and during the COVID-19 pandemic, and
estimated how antibody titres against seasonal influenza waned during the first two years of
the pandemic.

Findings

Low country-level prevalence of influenza virus (sub)types over one or more years occurred
frequently before the COVID-19 pandemic and had relatively small impacts on subsequent
epidemic size and severity. Additionally, antibody titres against seasonal influenza viruses
waned negligibly during the first two years of the pandemic.

Interpretation

The commonly held notion that lulls in influenza virus circulation, as observed during the
COVID-19 pandemic, will lead to larger and/or more severe subsequent epidemics might not
be fully warranted, and it is likely that post-lull seasons will be similar in size and severity to
pre-lull seasons.

Funding

Research in context

Evidence before this study

During the first years of the COVID-19 pandemic, the incidence of seasonal influenza was unusually low, leading to widespread concerns of exceptionally large and/or severe influenza epidemics in the coming years. We searched PubMed and Google Scholar using a combination of search terms (i.e., "seasonal influenza", "SARS-CoV-2", "COVID-19", "low incidence", "waning rates", "immune protection") and critically considered published articles and preprints that studied or reviewed the low incidence of seasonal influenza viruses since the start of the COVID-19 pandemic and its potential impact on future seasonal influenza epidemics. We found a substantial body of work describing how influenza virus circulation was reduced during the COVID-19 pandemic, and a number of studies projecting the size of future epidemics, each positing that post-pandemic epidemics are likely to be larger than those observed pre-pandemic. However, it remains unclear to what extent the assumed relationship between accumulated susceptibility and subsequent epidemic size holds, and it remains unknown to what extent antibody levels have waned during the COVID-19 pandemic. Both are potentially crucial for accurate prediction of post-pandemic epidemic sizes.

Added value of this study

We find that the relationship between epidemic size and severity and the magnitude of circulation in the preceding season(s) is decidedly more complex than assumed, with the magnitude of influenza circulation in preceding seasons having only limited effects on subsequent epidemic size and severity. Rather, epidemic size and severity are dominated by season-specific effects unrelated to the magnitude of circulation in the preceding season(s). Similarly, we find that antibody levels waned only modestly during the COVID-19 pandemic.

Implications of all the available evidence

The lack of changes observed in the patterns of measured antibody titres against seasonal influenza viruses in adults and nearly two decades of epidemiological data suggest that post-pandemic epidemic sizes will likely be similar to those observed pre-pandemic, and challenge

93   the commonly held notion that the widespread concern that the near-absence of seasonal

94   influenza virus circulation during the COVID-19 pandemic, or potential future lulls, are

95   likely to result in larger influenza epidemics in subsequent years.

Introduction

Seasonal influenza viruses typically cause annual epidemics worldwide, infecting up to 35% of the human population.[1,2] However, the incidence of seasonal influenza was unusually low during the first two years of the COVID-19 pandemic,[3,4] likely due to non-pharmaceutical interventions (NPIs) aimed at reducing transmission and spread of SARS-CoV-2, which are also effective in limiting exposure to seasonal influenza viruses.[5–8] This global lull in influenza virus circulation and consequent lack of immune stimulation led to widespread concerns of increased susceptibility to seasonal influenza viruses due to waning immunity, potentially resulting in larger and more severe epidemics in upcoming seasons, with studies predicting substantial increases in epidemic size.[6,9–12] Importantly, however, these studies fundamentally rely on assumptions concerning the relationship between accumulated susceptibility and influenza epidemic size. Similarly, the results of these studies are strongly influenced by assumed, but unmeasured, dynamics of antibody waning within such a period of abnormally reduced circulation.

Here, we performed a data-driven investigation into the extent to which prolonged periods of absence of influenza virus circulation, such as seen during the COVID-19 pandemic, can be expected to lead to larger and more severe subsequent epidemics. First, we analyzed two decades of epidemiological data from 47 countries to investigate the frequency of influenza lulls in the past and their effects on subsequent epidemic size and severity. Second, to interrogate the effects of lulls in influenza virus circulation on influenza antibody dynamics, we investigated the extent to which antibody titres against seasonal influenza viruses waned during the COVID-19 pandemic, using serum samples collected longitudinally before and during the COVID-19 pandemic from adults living in the Netherlands.

Methods

Epidemiological analysis

To gain insights into the expected effects of influenza circulation lulls on post-lull influenza epidemic sizes, we investigated the effects that past (sub)type lulls had on subsequent (sub)type epidemic size. We analyzed virological surveillance data for 47 countries in the Northern and Southern Hemispheres for the period from 2002 until 2019, deposited in the WHO FluNet database.[13] We identified (sub)type lull periods as consecutive seasons in

which a particular (sub)type was not dominant, for a particular country, where we defined
(sub)type dominance as a (sub)type accounting for ≥30% of detections in a particular
country, in a particular season. Here, a (sub)type being dominant in two consecutive seasons
corresponds to a lull duration of one.

Additionally, we estimated (sub)type-specific relative epidemic sizes for 20 countries in
Europe and the Middle East by integrating virological surveillance data with influenza-like
illness (ILI) data from the WHO FluID database.[14] In these estimates, a relative size of one
corresponds to the mean number of influenza virus infections in a single season for a given
country, irrespective of (sub)type.

We used Bayesian hierarchical models to investigate the effects of multiple metrics of the
magnitude of influenza virus circulation in preceding years on relative epidemic size. To
investigate the effect of magnitude of prior incidence on epidemic severity, we compared our
computed lull durations to estimated rates of Europe-wide influenza-specific excess mortality
as calculated prior by the EuroMOMO network,[15,16] which we use as a proxy for severity.
Please see the Supplementary Appendix for full methodological details of all analyses
outlined here.

Antibody model

To investigate antibody dynamics during the COVID-19 pandemic, we measured antibody
titres with haemagglutination inhibition (HI) assay against representative strains of each
(sub)type of seasonal influenza (A/H3N2: A/Netherlands/04189/2017; A/H1N1pdm09:
A/Netherlands/10218/2018; B/Yamagata: B/Netherlands/04136/2017; B/Victoria:
B/Netherlands/00302/2018), in longitudinal serum samples collected in the summer of 2020
and 2021 from 100 male adults within the Amsterdam Cohort Studies on HIV infection and
AIDS (ACS),[17] as well as 130 serum samples from a longitudinal cohort of adult COVID-19
patients (the Viro-immunological, clinical and psychosocial correlates of disease severity and
long-term outcomes of infection in SARS-CoV-2 – a prospective cohort study
(RECoVERED)).[18] To compare intra-pandemic against pre-pandemic influenza antibody
dynamics, we additionally measured HI titres to the same strains for the same ACS
individuals using serum samples collected in the summer of 2017, 2018 and 2019, yielding a
total of 630 serum samples across both cohorts. Importantly, all ACS individuals were HIV-

seronegative. Individuals from the RECoVERED cohort were confirmed to have not been
vaccinated for influenza in 2020.

We used a mathematical model to estimate antibody waning rates, based on the measured
haemagglutination inhibition antibody titres, with a Markov Chain Monte Carlo (MCMC)
algorithm used to explore the distribution of model parameters and augmented data. Full
details on virus selection, virus propagation, cohort details, HI assay used and the antibody
waning model can be found in the Supplementary Appendix.

Role of the funding source

164 The funder of the study had no role in study design, data collection, data analysis, data
165 interpretation, or writing of the report.

Results

Effects of past (sub)type lulls on subsequent (sub)type epidemic size

Prior to the COVID-19 pandemic, seasonal influenza virus circulation was highly
heterogeneous, with individual influenza epidemics in any given country typically being
dominated by one or two influenza virus (sub)types, leading to frequent lull periods lasting 1-
3 years where other seasonal influenza virus subtypes barely circulated. Due to the lack of
immunological cross-reactivity between (sub)types, these lulls are potentially analogous to
the scenario observed in the first two years of the COVID-19 pandemic for individual
(sub)types. Hence, they should yield insight into the effects of these lulls on epidemic size.

Between 2003 and 2020, low or near-absent circulation of an influenza virus (sub)type within
a single season occurred frequently, accounting for 41%, 48%, and 62% of all country-season
pairs for A/H3N2, A/H1N1pdm09 and influenza B viruses, respectively. In 53%, 56%, and
88% of country-season pairs for A/H3N2, A/H1N1pdm09, and B viruses, respectively,
(sub)type lulls lasted for more than one year, with some lull periods lasting as long as three
years (Fig. 1a). This indicates that extended periods of relative absence of individual
influenza (sub)types are a regular feature of influenza epidemic dynamics. Very small or
absent (sub)type-specific epidemics (*i.e.* relative epidemic sizes < 0·1, corresponding to 10%
of the mean influenza epidemic size) were observed for 28%, 23%, and 37% of country-
seasons for A/H3N2, A/H1N1pdm09 and influenza B viruses, respectively (Fig. 1b).

Fig. 1. The effects of previous years' influenza virus circulation on epidemic size and composition. a, The distribution of lull period durations, by (sub)type, across all country-season pairs. A lull duration of one corresponds to the same (sub)type's dominance in the previous season and presence in the current season. **b,** The distribution of relative epidemic sizes by virus (sub)type, across all countries and seasons. **c,** The probability of (sub)type dominance as a function of years since previous dominance. Error bars correspond to 95% confidence interval from an exact two-tailed binomial test for proportions. **d,** Relative size of a (sub)type-specific epidemic as a function of number of years since previous dominance of that (sub)type in that country, colored by season. Each point corresponds to a country-season pair, colored by the season. **e,** Relative size of a subtype's epidemic as a function of its size in the previous season and the sum of the two previous seasons' sizes. Each point corresponds to a country-season pair, colored by the season.

Investigating the effect influenza virus (sub)type lulls had on epidemic composition and size, we found that although both the probability of a (sub)type's dominance and the mean epidemic sizes for each influenza virus (sub)type increased with time since previous dominance (Fig. 1c-d), epidemic sizes varied substantially for each value of years since last

dominance (Fig. 1d). This suggests that background variation in epidemic size, independent
of absence or presence of circulation in preceding years, is substantial. Similarly, while there
is a negative relationship between the relative epidemic size of each (sub)type to its relative
size in the preceding year and the relative summed size over the last two years, there is wide
variation in epidemic size: seasons with very low and very high relative sizes both occurred
frequently following years of low-to-mid incidence (Fig. 1e). Notably, in 9 of the 20
countries included in our dataset, the first A/H3N2-dominant season (2011/2012) after the
2009 A/H1N1pdm09 pandemic did not belong to the three largest A/H3N2 epidemics in the
influenza seasons from 2010/2011 until 2019/2020, despite three years of near-absent
circulation.

**Fig. 2. Bayesian hierarchical model correlating relative influenza (sub)type epidemic
size to time since previous dominance, previous epidemic sizes and season-specific
effects.** Posterior distributions of parameter estimates in the model, with one year since
previous dominance (circles), previous epidemic size (diamonds), or sum of previous two
epidemics' size (squares) as predictors, either with or without season effects. Points, thick
and thin lines correspond to the posterior mean, 50% CI, and 95% CIs, respectively.

Importantly, for each number of years since dominance, we observed a striking degree of
clustering of relative epidemic sizes across countries by season, suggesting the existence of
season-specific effects on epidemic size, shared among countries in a single season (Fig. 1d).
For example, in the 2013/2014 and 2016/2017 seasons, where A/H3N2 dominated in most
countries two years prior, the relative incidence in 2016/2017 appeared consistently higher

than in 2013/2014. We thus hypothesized that the size of (sub)type-specific epidemics could be jointly explained by a combination of season-specific effects shared among countries and effects related to the presence or absence of that virus (sub)type in the years preceding an epidemic. We used a Bayesian hierarchical model to estimate the likely effects of years since dominance, size in the previous year and the sum of previous two seasons' sizes, as well as season-specific effects, on epidemic size (Fig. 2). The season effects correspond to the predicted 'base size' of a country's epidemic in a particular season, independent of the magnitude of prior circulation. Each of the three predictors individually had non-trivial effects on epidemic size in models with season effects and estimated effects were substantially smaller than in models that did not include season effects (Fig. 2).

Crucially, across all model formulations, the estimated season effects, shared among countries, differed substantially between seasons. Models that included season effects exhibited much better predictive performance than models without season effects (Supplementary Fig. 1), and between-season differences with regard to season effects were consistently substantially greater in magnitude than any of the predictors related to prior incidence. For example, in the model that includes previous season size as predictor for A/H3N2 epidemic size, the estimated season effects ('base sizes') ranged from 0·17 (95% CI 0·04-0·31) in 2015/2016 to 0·83 (95% CI 0·75-0·92) in 2016/2017: a difference of 0·66. Conversely, assuming the size of the previous season was the mean A/H3N2 season relative size (across all included countries and seasons), the effect of previous season size would only decrease predicted size by 0·06 (95% CI 0·01-0·12) compared to if there were no circulation in the previous season. Together, these results suggest that there is only a limited impact of the magnitude of influenza virus circulation in the preceding season(s) on subsequent epidemic size, consistent with previous work,[19] and that epidemic size is dominated by season-specific factors, unrelated to the magnitude of prior circulation.

Effects of past (sub)type lulls on subsequent influenza season severity

To investigate the effect of low influenza virus circulation on subsequent influenza season severity, as opposed to size, we compared our computed lull durations to Europe-wide estimates of excess mortality as calculated by the EuroMOMO network.[15,16] Rates of pooled Europe-wide influenza-attribute excess mortality varied substantially between seasons, ranging from 0·31 (95% CI 0·24-0·38) per 100,000 in 2013/2014 to 28·58 (95% CI: 28·22-28·95) per 100,000 in 2014/2015. Hence, in the decade prior to the COVID-19 pandemic,

epidemics could differ by up to two orders of magnitude in their severity.[15,16] In the

2011/2012 season, which was A/H3N2-dominant Europe-wide and followed a three-year

A/H3N2 lull in almost all countries, Europe-wide total excess mortality in the winter period

amounted to 6·73 (95% CI 5·26-8·21) per 100,000. In turn, in the 2014/2015 and 2016/2017

seasons, which were also A/H3N2-dominant Europe-wide and followed lull periods of one

and two years in almost all countries, respectively, influenza-specific excess mortality

amounted to 28·58 (95% CI: 28·22-28·95) and 25·65 (95% CI: 25·26-26·05) per 100,000,

respectively.[15,16] Hence, in these seasons, influenza-specific excess mortality was four-to-five

fold higher than total winter period excess mortality in 2011/2012, despite substantially

shorter lull durations. While this coarse analysis can only be performed for seasons

dominated by a single (sub)type, these results suggest that there is no clear relationship

between the magnitude of circulation in the preceding seasons and the severity of subsequent

seasons.

Antibody responses to seasonal influenza virus during the COVID-19 pandemic

Waning of pre-existing immunity due to lack of immune stimulation has been posited to lead

to larger post-lull epidemics, but evidence is lacking on precisely to what degree antibody

immunity against seasonal influenza viruses might change during near-absence of seasonal

influenza, as seen in the COVID-19 pandemic. To explicitly quantify the effects of lack of

influenza virus circulation on antibody titres against seasonal influenza viruses, we performed

an analysis of influenza antibody dynamics in the pre- and intra-COVID-19 pandemic period

in the Netherlands. We quantified the baseline antibody titres of an adult population in the

Netherlands for the seasons preceding the COVID-19 pandemic and the extent of their

decrease during the pandemic. Importantly, antibody responses to the haemagglutinin protein

of influenza viruses are known to be correlates of protection.[20–22]

From 2019 to 2021, mean HI titres remained largely unchanged for all influenza virus

(sub)types, including during the COVID-19 pandemic period, for both the ACS and

RECoVERED cohorts (Fig. 3b, Supplementary Fig. 4b). Influenza A/H3N2, A/H1N1pdm09

and B/Yamagata viruses had caused epidemics in the three influenza seasons prior to the

onset of the COVID-19 pandemic (Fig. 3a) and epidemic activity during this period was

consistent with patterns from 2010-2019 (Supplementary Fig. 2). For all seasonal influenza

virus (sub)types, mean HI titres increased after the 2017/2018 influenza epidemic but

returned to pre-2017/2018 levels by summer 2019 in the ACS cohort (Fig. 3b, Supplementary

Fig. 4b). Differentiating the year-on-year individual HI titre distributions by titre rises that are indicative of recent influenza virus infection (≥4-fold increase, ≥2 log₂ units), showed that influenza A and B virus infections were most common in individuals with low antibody titres in the year prior to infection (Fig. 3c, Supplementary Fig. 4c); consistent with lower antibody titers being associated with greater risk of infection. Overall, the HI titre distributions of the cohort remained largely unchanged over the study period, including during the first two years of the COVID-19 pandemic.

Fig. 3. Waning antibody titres to seasonal influenza virus before and during the COVID-19 pandemic. a, Individual antibody titres against seasonal influenza viruses based on haemagglutination inhibition (HI) assay from 2017-2021 among 70 healthy male adult participants of the Amsterdam Cohort Studies on HIV infection and AIDS (ACS) cohort for each influenza virus (sub)type as well as 65 male and female participants of the RECoVERED cohort for years 2020-21 (dashed). Mean antibody tires changes across all individuals are drawn in bold lines with error bars indicating the mean standard error. **b**, Seasonal influenza virus epidemic activity 2017-2021 in the Netherlands based on virological and syndromic surveillance data. **c**, HI titre distributions in the two cohorts following each winter epidemic period colored by influenza virus (sub)type. HI titre distributions of individuals who experienced a ≥2 log₂ units increase in HI titre (≥4-fold increase in HI titre), indicating likely infection in the next winter epidemic period, are shown in grey bars. **d**, Mean HI antibody titre waning rates by influenza virus (sub)type in adults estimated from HI

titres from 70 ACS and 65 RECoVERED participants. Error bars correspond to the 50% and 95% credible interval from the Markov Chain Monte Carlo algorithm used to explore the distribution of model parameters. Waning rate of -1.0 corresponds to one two-fold decrease in antibody titre in one year.

We applied a mathematical model on the HI titres of participants in 2020 and 2021 to estimate pandemic-period antibody titre waning rates. For the ACS individuals, we estimated that antibody titres against A/H3N2 viruses waned at -0·20 $\log_2$ units per year, 95% credible interval (CI) (-0·24, -0·16); A/H1N1pdm09 viruses at -0·10, 95% CI (-0·12, -0·07); B/Victoria viruses at -0·13, 95% CI (-0·16, -0·10); and B/Yamagata viruses at -0·14, 95% CI (-0·17, -0·11) (Fig. 3d, Supplementary Fig. 4d). For the RECoVERED cohort, we estimated mean waning rates towards A/H3N2, A/H1N1pdm09, B/Yamagata, and B/Victoria to be -0·15, 95% CI (-0·31, 0·01), -0·08, 95% CI (-0·19, 0·03), -0·08, 95% CI (-0·20, 0·04) and -0·10, 95% CI (-0·22, 0·02) $\log_2$ units per year respectively, in agreement with those derived from the ACS cohort (Fig. 3d). Combining data from both cohorts for the 2020-2021 period, the estimated mean waning rates remained similar to previous estimates for A/H3N2, A/H1N1pdm09 and B/Yamagata, and negligible for B/Victoria. We also calculated mean waning rates using HI titres from the same ACS individuals for the entire 2017-2021 period (Fig. 3d, Supplementary Fig. 4d), including only individuals who were likely not infected during the 2017-2021 period (*i.e.* no ≥2 $\log_2$ unit increases in HI titre for the entire study period). For this period, no significant waning of HI titres against any of the viruses was observed either, and estimates were similar to estimates for the 2020-2021 period, for both the ACS and the RECoVERED cohorts. We stratified baseline antibody titres by age and sex, for each (sub)type, but found no consistent age- or sex-related effects on baseline titres (Fig. 4a) or antibody waning rates (Fig. 4b). Measurement error was found to be consistent in both datasets at 0·38, 95% CI (0·36, 0·40) and 0·33, 95% CI (0·31, 0·36) $\log_2$ units for the full ACS and RECoVERED cohorts respectively, corresponding to a one-sided probability of a 2-fold error of approximately 5 −11%.

Fig. 4. The effects of age and sex on baseline antibody titre and waning rate. a, A cross section of antibody titres for both cohorts in 2021, broken down by (sub)type, age and sex. **b,** Individual fitted waning rates with 50% (thick lines) and 95% (narrow lines) CIs for the ACS 2017-21 and RECoVERED 2020-21 data, broken down by strain, age and sex.

Discussion

Our analysis of two decades of epidemiological data from 47 countries demonstrates that low country-level prevalence of influenza (sub)types over one or more years was not unique to the COVID-19 pandemic and occurred frequently in the past, and that periods or low or near-absent circulation of particular (sub)types did not necessarily lead to substantially increased epidemic sizes. Additionally, Bayesian statistical modelling shows that the magnitude of a (sub)type's circulation in preceding years had only limited effect on subsequent size. Instead, the strong clustering of different countries' epidemic size within particular seasons, supported by statistical modelling, suggests that epidemic size is more likely influenced by season-specific effects that are unrelated to the absence or presence of circulation in the prior season(s). The precise determinants of these season effects are likely manifold, including factors like the flux of viral seeding, heterosubtypic competition, and antigenic novelty.[19,23,24] Similarly, the severity of influenza seasons appears to be largely independent of the magnitude of influenza virus circulation in the preceding seasons. Importantly, this means that even if there were substantial accumulation of susceptibility, for example during the COVID-19 pandemic, it is likely that its effect on epidemic size and severity would be dwarfed by inherent season-to-season variation in epidemic size, unrelated to the absence or presence of substantial circulation in preceding years.

We showed that HI-measured immune protection against recent seasonal influenza viruses remained largely unchanged in adults since the start of the COVID-19 pandemic. Our analysis also suggests that substantial waning of antibody titres against seasonal influenza viruses occurs at timescales substantially longer than the lull in seasonal influenza virus circulation during the first two years of the COVID-19 pandemic[10]. Crucially, this analysis demonstrates that waning rates previously used to project post-COVID-19 lull epidemic sizes (e.g. waning of immunity within a single year[9], two to four years[6], or forty weeks[12]) are too high, and that waning rather happens on longer timescales, even following periods of absent circulation, in agreement with waning rates previously reported for adults during regular periods of influenza virus circulation.[25]

The serum samples were collected in two independent cohorts, with substantial diversity in age and sex, accounting for the elderly but excluding children. Due to the complex effects of immunosenescence, the elderly potentially exhibit differing antibody dynamics. Whilst studies have shown that vaccine-mediated protection wanes modestly quicker in those over

65 years of age,[26,27] there is little evidence to support the notion that serum antibodies wane

significantly faster for this age group. Our results showed similar antibody baseline titres and

waning rates for adults below and above 65 years of age, suggesting that serum antibodies in

both subgroups wane at similar rates.

Due to the lack of children in our serological analysis, the extent to which their waning rates

have changed since the start of the COVID-19 pandemic remains uncertain. Immune

dynamics in children are known to differ from those in adults,[28] with potentially higher

waning rates, which could lead to increased susceptibility to infection. Furthermore, the

accrual of additional birth cohorts during prolonged periods of absence of influenza virus

circulation might affect epidemic dynamics. However, the same dynamics of waning in

children and population turnover also occurred in pre-pandemic (sub)type lulls and are thus

fully incorporated in our epidemiological analyses. As such, the absence of child sera is

unlikely to bias our conclusions.

We used influenza-like illness data from the WHO FluID database and virologically

confirmed data from the WHO FluNet database in our epidemiological analyses. Bias might

affect both data sources. In particular, the FluID ILI data is non-influenza-specific, and

FluNet data might be biased due to e.g. the presence of convenience samples and

overrepresentation of outpatient surveillance. However, the observed consistency in the

estimated (sub)type-specific epidemic sizes across the 20 countries included in the analysis

for any given season suggests that these data sources broadly capture influenza

epidemiological dynamics. Therefore, our results are unlikely to be substantially affected by

potential year-on-year differences in reporting behavior or unrepresentative sampling.

Additionally, the applicability of our analysis to the post-COVID-19 pandemic-like situation

is predicated on the absence of substantial heterosubtypic immunity. Importantly,

heterosubtypic protection has previously been estimated to be exceedingly short-lived, with

duration on the order of a single day.[28] While we could only perform our severity analysis

using Europe-wide excess mortality data, the clustering of epidemic sizes within seasons

across European countries as observed in our epidemiological analysis suggests that, for any

given season, Europe-wide severity data is likely representative of the country level.

Although participants in the RECoVERED cohort were confirmed to be unvaccinated during

the study period, vaccination status for the ACS cohort was not known. However, in the

Netherlands individuals <60 years of age are only eligible for influenza vaccination if they

have underlying health conditions, and assuming population-wide rates of influenza vaccine

uptake in the Netherlands, only 3% of the ACS individuals, who importantly were all HIV-
seronegative, would be expected to be vaccinated. This, combined with the similarity in
antibody baseline titres and waning rates when comparing adults below and above 60 years of
age, suggests that lack of vaccination status for the ACS cohort is unlikely to bias our
conclusions.

Caution is required when looking at the size of post-pandemic seasonal influenza epidemics
as the COVID-19 pandemic has brought about immense changes in testing behavior, which
render the direct comparison of epidemic sizes before and immediately after the pandemic
difficult. However, preliminary insight into the effects of COVID-19 pandemic related
absence of circulation can be gained from Australia, where surveillance data shows that the
2022 influenza season was not greater in size than the range of epidemic sizes observed in the
decade prior to the COVID-19 pandemic.[29]

Past studies into the possible effects of a lull in influenza circulation on subsequent epidemic
size have assumed that the relationship between accumulation of susceptibility and epidemic
size can be predicted using standard SIR-type epidemic models. Here, we show that this
relationship is decidedly more complex, and that season-to-season variation in epidemic size
is dominated by factors not captured in current SIR models, with only a relatively small effect
of the magnitude of epidemics in the preceding year(s). Additionally, our results show that
antibody titres to influenza viruses waned marginally during the COVID-19 pandemic, and to
a smaller extent than assumed in modelling studies. Using multiple sources of data to add
nuance to a complex issue, our results challenge the commonly held notion that post-lull
influenza epidemics will be substantially larger and/or more severe.

Contributors

S.P.d.J., Z.C.F.G., J.C.G., A.X.H., D.E., M.D.d.J., and C.A.R. designed the research;
Z.C.F.G, S.v.L., M.v.H., K.d.H., and L.E.v.G executed the experimental work; Z.C.F.G. and
S.v.L. generated the antibody titre data; E.W., G.J.d.B, H.D.G.v.W., A.M., M.B., L.v.d.H.,
M.P., N.K., and M.D.d.J. collected the clinical samples; R.P.d.V. and G.J.B. made and
provided the glycan remodelled turkey red blood cells; S.P.d.J. and J.C.G. implemented the
modelling work and performed the data analysis; S.P.d.J.,Z.C.F.G., J.C.G., A.X.H., K.D.H.,
B.E.N., and C.A.R. wrote the first draft of the paper. All authors contributed to the critical
revision of the paper.

Declaration of interests

447 We declare no competing interests.

Data sharing

Acknowledgements

A.X.H., Z.C.F.G. and C.A.R. were supported by ERC NaviFlu (No. 818353). J.G. and C.A.R.

were supported by NIH R01 (5R01AI132362-04). C.A.R. was also supported by an NWO

Vici Award (09150182010027). R.P.dV. was supported by ERC starting grant 802780 and a

Beijerinck Premium of the Royal Dutch Academy of Sciences. GJB was supported by the

Netherlands Organization for Scientific Research (NWO TOPPUNT 718.015.003) and by an

ERC advanced grant (101020769). The RECoVERED cohort is supported by NWO ZonMw

(No. 10150062010002) and the Public Health Service of Amsterdam (Research &

Development grant number 21-14). The Amsterdam Cohort Studies on HIV infection and

AIDS, a collaboration between the Public Health Service Amsterdam, the Amsterdam UMC

of the University of Amsterdam, Medical Center Jan van Goyen and the HIV Focus Center of

the DC-Clinics, are part of the Netherlands HIV Monitoring Foundation and financially

supported by the Center for Infectious Disease Control of the Netherlands National Institute

for Public Health and the Environment. We gratefully acknowledge the authors and

originating and submitting laboratories (supplementary information) for the reference

sequences retrieved from GISAID's EpiFlu Database used in this study. The authors thank all

ACS and RECoVERED study participants. We are also grateful to Mr. Reinier van der Palen

of the department of Chemical Biology and Drug Discovery, Utrecht University for his

practical assistance with turkey erythrocyte glycan remodeling.

References

1 Petrova VN, Russell CA. The evolution of seasonal influenza viruses. *Nat Rev*
Microbiol 2017; **16**: 47–60.
2 Cohen C, Kleynhans J, Moyes J, *et al.* Asymptomatic transmission and high
community burden of seasonal influenza in an urban and a rural community in South
Africa, 2017-18 (PHIRST): a population cohort study. *Lancet Glob Health* 2021; **9**:
e863–e874.
3 Olsen SJ, Winn AK, Budd AP, *et al.* Changes in Influenza and Other Respiratory
Virus Activity During the COVID-19 Pandemic - United States, 2020-2021. *MMWR*
Morb Mortal Wkly Rep 2021; **70**: 1013–9.
4 Laurie KL, Rockman S. Which influenza viruses will emerge following the SARS-
CoV-2 pandemic? *Influenza Other Respir Viruses* 2021; **15**: 573–6.
5 Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage
extinction during the COVID-19 pandemic? *Nat Rev Microbiol* 2021; **19**: 741–2.
6 Qi Y, Shaman J, Pei S. Quantifying the Impact of COVID-19 Nonpharmaceutical
Interventions on Influenza Transmission in the United States. *J Infect Dis* 2021; **224**:
1500–8.
7 Huang QS, Wood T, Jelley L, *et al.* Impact of the COVID-19 nonpharmaceutical
interventions on influenza and other respiratory viral infections in New Zealand. *Nat*
Commun 2021; **12**: 1001.
8 Feng L, Zhang T, Wang Q, *et al.* Impact of COVID-19 outbreaks and interventions on
influenza in China and the United States. *Nat Commun* 2021; **12**: 3249.
9 Ali ST, Lau YC, Shan S, *et al.* Prediction of upcoming global infection burden of
influenza seasons after relaxation of public health and social measures during the
COVID-19 pandemic: a modelling study. *Lancet Glob Health* 2022; **10**: e1612–22.
10 Dhanasekaran V, Sullivan S, Edwards KM, *et al.* Human seasonal influenza under
COVID-19 and the potential consequences of influenza lineage elimination. *Nat*
Commun 2022; **13**: 1721.
11 Jones N. Why easing COVID restrictions could prompt a fierce flu rebound. *Nature*
2021; **598**: 395.
12 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of
COVID-19 nonpharmaceutical interventions on the future dynamics of endemic
infections. *Proc Natl Acad Sci U S A* 2020; **117**: 30547–53.
13 World Health Organization (WHO). FluNet. Available at:
https://www.who.int/tools/flunet.
14 World Health Organization (WHO). FluID. Available at:
https://www.who.int/teams/global–influenza–program.
15 EuroMOMO Network.. EuroMOMO Winter Season 2015/16 Mortality Summary
Report. Available at:
https://www.euromomo.eu/uploads/pdf/winter_season_summary_2015_16.pdf.

16 Nielsen J, Vestergaard LS, Richter L, *et al.* European all-cause excess and influenza-
attributable mortality in the 2017/18 season: should the burden of influenza B be
reconsidered? *Clinical Microbiology and Infection* 2019; **25**: 1266–76.

17 van Bilsen WPH, Boyd A, van der Loeff MFS, *et al.* Diverging trends in incidence of
HIV versus other sexually transmitted infections in HIV-negative MSM in
Amsterdam. *AIDS* 2020; **34**: 301–9.

18 Wynberg E, van Willigen HDG, Dijkstra M, *et al.* Evolution of Coronavirus Disease
2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. *Clinical*
Infectious Diseases 2021; published online Sept. DOI:10.1093/cid/ciab759.

19 Lam EKS, Morris DH, Hurt AC, Barr IG, Russell CA. The impact of climate and
antigenic evolution on seasonal influenza virus epidemics in Australia. *Nat Commun*
2020; **11**: 2741.

20 Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza Hemagglutination-
Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. *J Infect Dis*
2011; **204**: 1879–85.

21 Tsang TK, Perera RAPM, Fang VJ, *et al.* Reconstructing antibody dynamics to
estimate the risk of influenza virus infection. *Nat Commun* 2022; **13**: 1557.

22 Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship
between haemagglutination-inhibiting antibody titres and clinical protection against
influenza: development and application of a bayesian random-effects model. *BMC*
Med Res Methodol 2010; **10**: 18.

23 Bedford T, Suchard MA, Lemey P, *et al.* Integrating influenza antigenic dynamics
with molecular evolution. *Elife* 2014; **3**: e01914.

24 Axelsen JB, Yaari R, Grenfell BT, Stone L. Multiannual forecasting of seasonal
influenza dynamics reveals climatic and evolutionary drivers. *Proceedings of the*
National Academy of Sciences 2014; **111**: 9538.

25 Fonville JM, Wilks SH, James SL, *et al.* Antibody landscapes after influenza virus
infection or vaccination. *Science* 2014; **346**: 996–1000.

26 Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ.
Waning vaccine protection against influenza A (H3N2) illness in children and older
adults during a single season. *Vaccine* 2015; **33**: 246–51.

27 Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, *et al.* Waning protection of
influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. *Vaccine*
2017; **35**: 5799–807.

28 Ranjeva S, Subramanian R, Fang VJ, *et al.* Age-specific differences in the dynamics of
protective immunity to influenza. *Nat Commun* 2019; **10**: 1660.

29 Department of Health and Aged Care. Australian Government. Australian Influenza
Surveillance Report No. 14, 2022. Available at:
https://www1.health.gov.au/internet/main/publishing.nsf/Content/B4F29E7D594818E
BCA2588DB000EA9D2/$File/flu-14-2022.pdf (accessed Oct 25, 2022).